LXE Hearing

LXE Hearing is a health technology company that provides innovative solutions for hearing loss detection and intervention through clinically validated products and accessible services. LXE Hearing is focused on developing advanced solutions for hearing loss detection and intervention. Founded in 2025 in San Jose, US, the company has secured a total of USD 100. 00 mn in funding, with its latest round completed on March 31, 2025, from Patient Square Capital.

LXE Hearing has executed 1 deal to date, reflecting its commitment to expanding its impact in the healthcare sector. The founder’s information and history are not publicly available, and there is no mention of subsidiaries or pivots in business strategy. LXE Hearing specializes in health technology solutions for hearing loss. The company offers core products such as Eargo, featuring virtually invisible hearing aids sold directly to consumers, and Lexie Hearing, the leading over-the-counter hearing aid brand in the United States.

Lexie Hearing's acclaimed Powered by Bose line stands out for its technological advancements, while hearX provides mobile, affordable, and clinically validated technologies for hearing loss detection, applicable in various settings without soundproof booths. The products are available in over 70 countries, with a strong retail presence of more than 16,000 stores across the United States, addressing diverse demographic needs. LXE Hearing generates revenue primarily from direct-to-consumer sales and partnerships with retailers, particularly through its flagship brands Eargo and Lexie Hearing. Consumers can purchase hearing aids via retail outlets or online, benefiting from the innovative technology and clinical validation.

Lexie Hearing targets a broad consumer base seeking over-the-counter solutions, while hearX facilitates early detection services through its mobile technology across various healthcare settings. The pricing strategy reflects a commitment to affordable hearing wellness solutions, though specific pricing plans and revenue figures for individual products are not disclosed. In March 2025, LXE Hearing raised USD 100. 00 mn in venture funding from Patient Square Capital to support its initial business operations.

The company plans to develop and launch new products designed to enhance hearing loss intervention, with specific release dates not yet disclosed. Additionally, LXE Hearing targets expansion into new markets beyond the current 70 countries, although specific regions for this expansion are not detailed. The funding will be utilized to underpin these initiatives, promoting growth and accessibility in hearing health.